Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Alzheimer s & Dementia

Combined use of plasma p‐tau217, NfL, and GFAP predicts domain‐specific cognitive decline in cognitively unimpaired and MCI individuals

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChao‐Yi WuCLChen LiuHFHadia Fatima

Discussion

Loading...

Member takes

Overview

Assessment using biomarkers predicts cognitive decline in unimpaired and MCI individuals, highlighting Alzheimer’s disease risk.

Key Points

  • High levels of biomarkers indicate cognitive decline in both cognitively unimpaired and MCI individuals, suggesting early detection methods.
  • Gaussian mixture models classified participants based on biomarker levels, aiding in cognitive risk assessment.
  • The study involved 523 participants from the Massachusetts Alzheimer's Disease Research Center, focusing on cognitive domains.
  • These findings may enable improved cognitive decline monitoring through specific Alzheimer's disease biomarkers.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/6930dc6bea1aef094cca1ecdhttps://doi.org/10.1002/alz.70934
View Full Paper
Ask AI
Bookmark
Share